June 20, 2024, 2:59 PM ESTHealth Care May 23, 2024, 1:57 PM ESTHealth Care April 18, 2024, 9:54 AM EST April 17, 2024, 6:16 AM ESTHealth Care February 06, 2024, 10:38 AM ESTHealth Care November 03 ...

The largest U.S. drug industry group and several drug companies have lost a bid to block a Maryland law requiring drugmakers to offer discounts on drugs dispensed by third-party pharmacies that ...

These findings support the use of both neoadjuvant and adjuvant nivolumab in patients with resectable NSCLC, Patrick M. Forde ...

Response rates seen in patients with high-risk biochemically recurrent prostate cancer after radical prostatectomy.

Artificial intelligence and organoid advances hold new promise for reducing the number of laboratory animals used in studies.

The tumor-seeking radiopharmaceuticals are charting a new course in oncology, with promise for targeted treatments with fewer ...

Marshall, M.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues ... ties to pharmaceutical ...

Marshall, MD, of Johns Hopkins University School of Medicine in Baltimore, Maryland ... for those patients,” the authors concluded. AstraZeneca, which markets olaparib, provided the drug ...

Martin, MD, MHS, both of the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease in Baltimore ... Arrowhead, AstraZeneca, Baim Institute, Beth Israel Deaconess Medical ...

As researchers estimate that nearly all Americans have been exposed to SARS-CoV-2, the virus that causes COVID-19, whether ...

At a thrombosis research center, an observational study is underway investigating the impact of numerous biomarkers on ...

Cambridge Antibody Technology (CAT; Slough, UK) also received $1.1 billion when AstraZeneca purchased ... stem cell company Osiris Therapeutics (Baltimore), whose price leapt 130% on news that ...